Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,

Slides:



Advertisements
Similar presentations
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Advertisements

How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,
Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 
Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease  Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
YouTube® and inflammatory bowel disease
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report  Andreia Albuquerque, Fernando Magro,
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 
Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
Microscopic colitis patients have increased proportions of Ki67+ proliferating and CD45RO+ active/memory CD8+ and CD4+8+ mucosal T cells  Ashok Kumar.
Anterior ischemic optic neuropathy in a patient with Crohn's disease and aberrant MTHFR and GPIIIa gene variants  T. Felekis, K.H. Katsanos, C.D. Zois,
The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD)  S. Malik, S.F. Ahmed, M.L. Wilson, N. Shah, S. Loganathan,
Serum prohepcidin levels in chronic inflammatory bowel diseases
Oral tacrolimus for pediatric steroid-resistant ulcerative colitis
Charlotte de Bie, Angelika Kindermann, Johanna Escher 
N. Kjaersgaard Nielsen, V. Wewer, L. Skafte, A. Paerregaard 
Fatal Colonic Perforation in a Pregnant with Behçet's Disease
Valle García-Sánchez, Eva Iglesias-Flores, Raúl González, Javier P
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years  May-Bente Bengtson, Camilla.
Public awareness of Crohn's disease and ulcerative colitis: A national survey  Sieglinde Angelberger, Harald Vogelsang, Gottfried Novacek, Wolfgang Miehsler,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
B. Sicilia, F. Arribas, J. Nerín, C. López Miguel, R. Vicente, F
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases  Danuta Owczarek,
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,
W. Dolak, J. Maresch, F. Kainberger, F. Wrba, Ch. Müller 
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery  G. Andrisani, L. Guidi, A. Papa, A.E. Potenza,
Volume 138, Issue 2, Pages (February 2010)
Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment.
Paula Borralho, Ana Vieira, João Freitas, Paula Chaves, Jorge Soares 
Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis?  Hans H. Herfarth, MD, PhD  Clinical.
Long-term outcome after infliximab for refractory ulcerative colitis
Clinical trials in luminal Crohn's disease: A historical perspective
M. Chaparro, P. Martínez-Montiel, M. Van Domselaar, F. Bermejo, J. L
Xian-rui Wu, Saurabh Mukewar, Ravi P. Kiran, Feza H
Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients  Marko Brinar, Séverine.
Illustrations in Ulcerative Colitis
Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis  Niels Teich, Tobias Klugmann  Journal of.
Seth Lipka, Seymour Katz, Lev Ginzburg  Journal of Crohn's and Colitis 
Osteoporosis in inflammatory bowel disease
Pediatric pulmonary Crohn's disease: More frequent than expected
“Ulcerative crepitus” — A case with subcutaneous emphysema and pneumomediastinum without colonic perforation or toxic megacolon in ulcerative colitis.
Suppurative granulomatous inflammation in the ileo-anal pouch
Ulrich Bonse-Geuking, Michael Kraus  Journal of Crohn's and Colitis 
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation  Sjoerd F. Bakker,
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA- based protocol in UK subjects with inflammatory bowel disease suitable.
Does active smoking really influence the course of Crohn's disease
Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function  Ulf Hindorf, Malin Lindqvist.
Yinghong Wang, Hua Gong, Rocio Lopez, Lei Lian, Ravi P. Kiran, Edy E
Surgical management of gluteal metastatic cutaneous Crohn's disease
Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab  Antonio López San Román, Manuel.
Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis  S.D. McLaughlin, A. Culkin,
Bowel sonography in occlusive Crohn's disease
Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors  Anilga Moradkhani, Linda.
National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey  Stefan.
Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.
Volume 157, Issue 4, Pages e6 (October 2019)
Presentation transcript:

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens, F. Baert, F. Fontaine, S. Vermeire, D. Franchimont, T. Moreels, D. Staessen, L. Terriere, B. Vander Cruyssen, E. Louis  Journal of Crohn's and Colitis  Volume 6, Issue 5, Pages 557-562 (June 2012) DOI: 10.1016/j.crohns.2011.11.002 Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Figure 1 Evolution of calprotectin levels under infliximab therapy in function of the induction of endoscopic remission at week 10. Legend: Boxplots describe medians and interquartile ranges of the completers Lines show the result of the mixed models analysis (ITT analysis). Journal of Crohn's and Colitis 2012 6, 557-562DOI: (10.1016/j.crohns.2011.11.002) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Figure 2 Evolution of calprotectin levels under infliximab therapy in function of the induction of endoscopic remission at week 10 and concomitant use of corticosteroids. Legend: Boxplots describe medians and interquartile ranges of the completers. Lines show the result of the mixed models analysis (ITT analysis). Journal of Crohn's and Colitis 2012 6, 557-562DOI: (10.1016/j.crohns.2011.11.002) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.